Skip to main content
Premium Trial:

Request an Annual Quote

SIRPant Immunotherapeutics Begins Phase I Trial of Autologous Macrophage Therapy

NEW YORK – SIRPant Immunotherapeutics on Tuesday said it dosed the first patient in a Phase I trial of its autologous activated macrophage therapy, SIRPant-M, as a treatment for relapsed or refractory non-Hodgkin lymphoma.

In the trial, SIRPant will evaluate SIRPant-M alone or in combination with focal external-beam radiotherapy in 24 patients who have received at least two lines of systemic therapy and who are ineligible for other treatment regimens with curative potential. Investigators will track the incidence of treatment-emergent adverse events as the primary outcome measure of the trial and, as secondary outcome measures, will determine the recommended Phase II dose and gauge objective response rate.

Christiane Querfeld, director of the multidisciplinary cutaneous lymphoma program at City of Hope where the patient was treated, said in a statement that the patient's initial response to SIRPant-M was "very encouraging, and I look forward to treating patients with advanced stage T-cell lymphoma, which generally relapse or become refractory to standard regimens that target tumor cells alone."

SIRPant-M uses tumor-specific neo-antigens to activate patients' own macrophages to recognize and eliminate cancer cells by targeting and removing the signal regulatory protein alpha (SIRPα) functions on macrophages, which inhibit immune response. The Hummelstown, Pennsylvania-based company developed the treatment using its PhagoAct platform.